Effects of medication on dopamine transporter imaging using [I]I-FP-CIT SPECT in routine practice.

Date publication

décembre 2023

Journal

European journal of nuclear medicine and molecular imaging

Auteurs

Membres identifiés du Cancéropôle Est :
Pr VERGER Antoine

Tous les auteurs :
Piatkova Y, Doyen M, Heyer S, Tahmazov A, Frismand S, Hopes L, Imbert L, Verger A

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/38114618

Résumé

Dopamine transporter (DAT) imaging is used to support the diagnosis of neurodegenerative parkinsonian disorders. Specific medications have been reported to confound the interpretation of [I]I-FP-CIT SPECT scans, but there is limited data. The aim of the current study is to identify potential medication effects on the interpretation of [I]I-FP-CIT SPECT scans in routine practice.

Mots clés

Antidepressants, DAT, Dopaminergic imaging, Drugs, FP-CIT, NASSA, Parkinson’s disease

Référence

Eur J Nucl Med Mol Imaging. 2023 12 20;: